Tharimmune Forms Scientific Advisory Board To Drive Clinical-Stage Lead In Chronic Liver Disease And Early-Stage Tunable Knob Domains For Generating Antibody Drug Conjugate Biotherapeutics
Tharimmune Forms Scientific Advisory Board To Drive Clinical-Stage Lead In Chronic Liver Disease And Early-Stage Tunable Knob Domains For Generating Antibody Drug Conjugate Biotherapeutics
Tharimmune成立科學顧問委員會，推動慢性肝病臨床階段的領先地位，以及用於生產抗體藥物偶聯生物療法的早期可調旋鈕域
Group includes leading experts in multiple disciplines including immunology, liver diseases, protein engineering, antibody drug conjugates and platform innovation
小組包括多個學科的領先專家，包括免疫學、肝臟疾病、蛋白質工程、抗體藥物偶聯物和平台創新
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。